Premaitha management changes add robustness

Premaitha management changes add robustness

Manchester-based Premaitha Health, the developer of a ground-breaking non-invasive prenatal test (NIPT) for Down’s Syndrome in unborn children, has announced a raft of management changes as the commercialisation of its IONA test begins to gather pace.

Chief medical officer Dr William Denman is to join the board of the AIM-listed company after being with the company for more than four year years. Meanwhile, the remit of Peter Collins will be broadened to take on the role of chief business officer.

Chairman David Evans said: “We look forward to the coming year, in which we will continue to prioritise the commercialisation of our test and product development. We intend to further develop our business through closer collaboration with key opinion leaders, our platform and distribution partners.”

The management reshuffle coincides with news that Premaitha and the Wolfson Institute – part of St Bart’s and the London School of Medicine and Dentistry and Britain’s leading research and service facility for antenatal screening for Down’s – are collaborating in a world first for NIPT, using the IONA test.

See article in full at TheBusinessDesk.com

 

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.